Scalper1 News
Shares of Puma Biotechnology were down 14% to around 193 in morning trading on the stock market today after the company said late Tuesday that it will file for FDA approval of its first drug a year later than expected. Puma (PBYI) said that it will file for approval of breast-cancer drug neratinib in the first quarter of 2016, after previously saying that it would file in the first half of 2015. The reason is that the company wants approval for an Scalper1 News
Scalper1 News